Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVG/FTC/TDF/cobicistat versus atazanavir/ritonavir plus FTC/TDF in treatment-naive adults with HIV-1
2009-016758-42Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing EVG/FTC/TDF/cobicistat fixed-dose combination with Atazanavir/ritonavir plus FTC/TDF (2 arms). Primary endpoint: Proportion of subjects achieving HIV-1 RNA below 50 copies/mL at Week 48. Started Mar 2010; status: completed.
02
Drugs
elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistatatazanavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-016758-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016758-42.